NLS Pharmaceutics Warrant
NLSPW
NLSPW was delisted on the 30th of October, 2025.
3 hedge funds and large institutions have $1.14K invested in NLS Pharmaceutics Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.8% less ownership
Funds ownership: 1.03% → 0.22% (-0.8%)
40% less funds holding
Funds holding: 5 → 3 (-2)
78% less capital invested
Capital invested by funds: $5.17K → $1.14K (-$4.03K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$3.19K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$821 |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7 |
| 4 |
CS
Clear Street
New York
|
-$4 |
NLSPW Hedge Fund Activity: Q1 2025 in Review
3 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2025, worth a combined $1.14K — down 78% from $5.17K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NLSPW and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Wolverine Asset Management, exiting entirely with an estimated $3.19K sold.
- 3 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2025, down from 5 in Q4 2024.
- Funds reported $1.14K of NLS Pharmaceutics Warrant stock for Q1 2025, down 78% quarter-over-quarter.
- 0 funds opened new NLS Pharmaceutics Warrant positions in Q1 2025 and 2 closed out, a net change of -2 holders.
- The largest NLS Pharmaceutics Warrant seller in Q1 2025 was Wolverine Asset Management, an estimated $3.19K sold.
Based on aggregated 13F filings for Q1 2025.